Inhibitor of bacterial vaginosis, inhibitor of autoinducer-2 of bacterial vaginosis-associated bacteria, inhibitor of biofilm formation of bacterial vaginosis-associated bacteria, enhancer of antibacterial power of antibiotic against bacterial vaginosis-associated bacteria, and method for enhancing the antibacterial power
Lactic acid and/or its salts address the challenges of bacterial vaginosis by inhibiting AI-2 and biofilm formation in Gardnerella vaginalis, enhancing antibacterial agent efficacy without adverse effects, providing a safe and effective treatment for bacterial vaginosis.
Patent Information
- Application Number
- JP2024052815
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-03-28
- Publication Date
- 2025-10-09
AI Technical Summary
Existing treatments for bacterial vaginosis, particularly those targeting Gardnerella vaginalis, face challenges due to the bacterium's quorum sensing mechanism using AI-2, leading to biofilm formation and drug resistance, with current inhibitors like subtilosin and benzoyl peroxide being difficult to obtain and their safety uninvestigated for intravaginal use.
Lactic acid and/or its salts are used as inhibitors to target AI-2, suppressing quorum sensing and biofilm formation by Gardnerella vaginalis without exerting antibacterial activity, and enhance the efficacy of antibacterial agents against biofilms.
Lactic acid and/or its salts effectively inhibit AI-2 and biofilm formation, suppressing bacterial vaginosis while maintaining safety for vaginal use and enhancing the antibacterial activity of other agents against biofilms.